2021
Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database
Tremblay D, Ronner L, Podoltsev N, Gotlib J, Heaney M, Kuykendall A, O'Connell C, Shammo JM, Fleischman A, Mesa R, Yacoub A, Hoffman R, Moshier E, Zubizarreta N, Mascarenhas J. Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. Leukemia Research 2021, 109: 106629. PMID: 34082375, DOI: 10.1016/j.leukres.2021.106629.Peer-Reviewed Original ResearchConceptsMulti-institutional databaseRuxolitinib discontinuationPolycythemia veraLarge multi-institutional databaseAvailable salvage therapiesDiscontinuation of ruxolitinibTreatment of patientsFurther therapeutic developmentLast followSalvage therapyCytoreductive therapyAdverse eventsPatient characteristicsThrombotic eventsTreatment initiationSimilar patientsDisease characteristicsDismal outcomeFavorable outcomeSalvage strategyPV patientsDiscontinuationInterferon αPatientsRuxolitinibA Phase I dose‐escalation study of DCLL9718S, an antibody‐drug conjugate targeting C‐type lectin‐like molecule‐1 (CLL‐1) in patients with acute myeloid leukemia
Daver N, Salhotra A, Brandwein JM, Podoltsev NA, Pollyea DA, Jurcic JG, Assouline S, Yee K, Li M, Pourmohamad T, Samineni D, Sumiyoshi T, Vaze A, Dere RC, Ma C, Cooper J. A Phase I dose‐escalation study of DCLL9718S, an antibody‐drug conjugate targeting C‐type lectin‐like molecule‐1 (CLL‐1) in patients with acute myeloid leukemia. American Journal Of Hematology 2021, 96: e175-e179. PMID: 33617672, PMCID: PMC8252033, DOI: 10.1002/ajh.26136.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodiesAntineoplastic AgentsChemical and Drug Induced Liver InjuryDose-Response Relationship, DrugEarly Termination of Clinical TrialsFemaleHumansImmunoconjugatesLectins, C-TypeLeukemia, Myeloid, AcuteMaleMiddle AgedMutationNeoplasm ProteinsNeoplasms, Second PrimaryReceptors, MitogenYoung AdultPatterns of Care for Older Patients With Myelofibrosis: A Population-based Study
Meckstroth S, Wang R, Ma X, Podoltsev N. Patterns of Care for Older Patients With Myelofibrosis: A Population-based Study. Clinical Lymphoma Myeloma & Leukemia 2021, 21: e551-e558. PMID: 33648884, DOI: 10.1016/j.clml.2021.01.025.Peer-Reviewed Original ResearchConceptsPatterns of careOlder patientsEnd Results-Medicare databaseJAK inhibitor eraHigh-risk patientsPopulation-based studyUse of ruxolitinibJAK inhibitor ruxolitinibUnited States FoodRuxolitinib approvalMedian ageMedian timeTreatment patternsD claimsCurrent treatmentInhibitor ruxolitinibPatientsBetter outcomesClinical experienceDrug AdministrationMedicare Part BMyelofibrosisRuxolitinibStates FoodNew drugsEpidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms
Shallis RM, Zeidan AM, Wang R, Podoltsev NA. Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms. Hematology/Oncology Clinics Of North America 2021, 35: 177-189. PMID: 33641862, DOI: 10.1016/j.hoc.2020.11.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2020
Sequencing of novel agents in relapsed/refractory B‐cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia
Badar T, Szabo A, Dinner S, Liedtke M, Burkart M, Shallis RM, Yurkiewicz IR, Kuo E, Khan MA, Balasubramanian S, Yang J, Hefazi M, Podoltsev N, Patel A, Curran E, Wang A, Arslan S, Aldoss I, Siebenaller C, Mattison RJ, Litzow MR, Wadleigh M, Advani AS, Atallah E. Sequencing of novel agents in relapsed/refractory B‐cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Cancer 2020, 127: 1039-1048. PMID: 33259056, DOI: 10.1002/cncr.33340.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntibodies, BispecificAntineoplastic Agents, ImmunologicalDrug Administration ScheduleDrug Resistance, NeoplasmFemaleHematopoietic Stem Cell TransplantationHumansInotuzumab OzogamicinMaleMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaRemission InductionRetrospective StudiesTreatment OutcomeWithholding TreatmentYoung AdultConceptsAcute lymphoblastic leukemiaRefractory B-cell acute lymphoblastic leukemiaB-cell acute lymphoblastic leukemiaMedian overall survivalINO groupNovel agentsOverall survivalLymphoblastic leukemiaComplete remissionInotuzumab ozogamicinNA therapyComparable efficacyRelapsed/refractory (r/r) B-cell acute lymphoblastic leukemiaAllogeneic hematopoietic stem cell transplantationCR/CRi rateIncomplete count recovery (CRi) ratesRefractory acute lymphoblastic leukemiaHematopoietic stem cell transplantationNovel agent therapyOutcomes of patientsStem cell transplantationBlinatumomab groupCRi rateTreatment discontinuationAdverse eventsDiet and Risk of Myeloproliferative Neoplasms in Older Individuals from the NIH-AARP Cohort
Podoltsev NA, Wang X, Wang R, Hofmann JN, Liao LM, Zeidan AM, Mesa RA, Ma X. Diet and Risk of Myeloproliferative Neoplasms in Older Individuals from the NIH-AARP Cohort. Cancer Epidemiology Biomarkers & Prevention 2020, 29: 2343-2350. PMID: 32868318, PMCID: PMC8895351, DOI: 10.1158/1055-9965.epi-20-0592.Peer-Reviewed Original ResearchConceptsRisk of MPNPolycythemia veraEssential thrombocythemiaMyeloproliferative neoplasmsHazard ratioSugar intakeDietary factorsMultivariable Cox proportional hazards modelsRisk of PVCox proportional hazards modelHigh sugar intakeNIH-AARP DietIntake of fatConfidence intervalsNIH-AARP cohortRole of dietProportional hazards modelPotential confounding variablesParticipants ages 50Warrants further investigationProspective cohortHigh intakePV riskAge 50Health StudyPhase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia
Cortes J, Podoltsev N, Kantarjian H, Borthakur G, Zeidan AM, Stahl M, Taube T, Fagan N, Rajeswari S, Uy GL. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. International Journal Of Hematology 2020, 113: 92-99. PMID: 32951163, DOI: 10.1007/s12185-020-02994-8.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsCell Cycle ProteinsDecitabineDose-Response Relationship, DrugFebrile NeutropeniaFeeding and Eating DisordersFemaleGene ExpressionHumansLeukemia, Myeloid, AcuteMaleMolecular Targeted TherapyProtein Serine-Threonine KinasesProto-Oncogene ProteinsPteridinesTreatment OutcomeConceptsAcute myeloid leukemiaMyeloid leukemiaCommon treatment-emergent adverse eventsPhase 1 dose-escalation trialTreatment-emergent adverse eventsMTD of volasertibObjective response rateAdverse event profileDose-escalation trialPhase 1 trialAnti-leukemic activityPolo-like kinase 1Febrile neutropeniaEscalation trialAdverse eventsCell cycle kinase inhibitorsAML patientsEvent profilePoor prognosisResponse ratePatientsVolasertibDecitabineKinase inhibitorsNumerous cancersPersistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis
Ronner L, Podoltsev N, Gotlib J, Heaney ML, Kuykendall AT, O’Connell C, Shammo J, Fleischman AG, Scherber RM, Mesa R, Yacoub A, Perkins C, Meckstroth S, Behlman L, Chiaramonte M, Salehi M, Ziadkhanpour K, Nguyen H, Siwoski O, Hung AK, Janania Martinez M, Nguyen J, Patel S, Kollipara R, Dave A, Randall M, Grant M, Harrison M, Fernandez Soto P, Tremblay D, Hoffman R, Moshier E, Mascarenhas J. Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood 2020, 135: 1696-1703. PMID: 32107559, PMCID: PMC7205813, DOI: 10.1182/blood.2019003347.Peer-Reviewed Original ResearchPatterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States
Zeidan AM, Podoltsev NA, Wang X, Zhang C, Bewersdorf JP, Shallis RM, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X, Wang R. Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States. Blood Advances 2020, 4: 1615-1623. PMID: 32311013, PMCID: PMC7189301, DOI: 10.1182/bloodadvances.2020001728.Peer-Reviewed Original ResearchConceptsIntensive induction chemotherapyAcute myeloid leukemiaHospital deathInduction chemotherapyAdult patientsMultivariable logistic regression modelLow hospital volumePremier Healthcare DatabasePredictors of deathHealthcare resource utilizationIntensive care unitPatterns of careStandard of careLogistic regression modelsFit patientsRemission inductionFirst hospitalizationHospital volumeInpatient deathInpatient mortalityOlder patientsSupportive careMedian ageAML patientsCare unitReal-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin
Badar T, Szabo A, Wadleigh M, Liedtke M, Arslan S, Siebenaller C, Aldoss I, Schultz E, Hefazi M, Litzow MR, Kuo E, Wang A, Curran E, Shallis RM, Podoltsev N, Balasubramanian S, Yang J, Mattison R, Burkart M, Dinner S, Advani A, Atallah E. Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. Clinical Lymphoma Myeloma & Leukemia 2020, 20: 556-560.e2. PMID: 32291234, DOI: 10.1016/j.clml.2020.03.004.Peer-Reviewed Original ResearchConceptsB-cell acute lymphocytic leukemia patientsAcute lymphocytic leukemia patientsAllo-HCTLymphocytic leukemia patientsInotuzumab ozogamicinOverall survivalLeukemia patientsAllogeneic hematopoietic stem cell transplantationMinimal residual disease negativityHematopoietic stem cell transplantationCommon grade 3Efficacy of iNOHigher adverse eventsMedian overall survivalMulticenter cohort analysisVeno-occlusive diseaseDuration of responseStem cell transplantationOverall response rateINO initiationComplete remissionMedian durationAdverse eventsMedian ageCumulative doseManagement of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study
Stahl M, Shallis RM, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, Konig H, Luger S, Khan I, Roboz GJ, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan JM, Mukherjee S, Brunner AM, Miller A, McMahon CM, Ritchie EK, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuña-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia 2020, 34: 3149-3160. PMID: 32132655, PMCID: PMC8155811, DOI: 10.1038/s41375-020-0783-3.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaOverall survivalMyeloid leukemiaMultivariate analysisLong-term clinical outcomesComposite complete remissionImpact of leukapheresisManagement of hyperleukocytosisMedian overall survivalThirty-day mortalityHigh-quality evidenceWhite cell countProportional hazards modelUse of leukapheresisLogistic regression modelsSignificant resource useIntensive chemotherapyComplete remissionHazard ratioClinical outcomesInferior outcomesUnadjusted analysesQuality evidencePotential complicationsOdds ratioDisseminated, yet dissembled: Rare infections behind the veil of classical hairy cell leukemia
Shallis RM, Patel TH, Podoltsev NA, Xu ML, Azar MM, Gore SD. Disseminated, yet dissembled: Rare infections behind the veil of classical hairy cell leukemia. Leukemia Research 2020, 90: 106315. PMID: 32036123, DOI: 10.1016/j.leukres.2020.106315.Peer-Reviewed Case Reports and Technical NotesLifestyle factors and risk of myeloproliferative neoplasms in the NIH‐AARP diet and health study
Podoltsev NA, Wang X, Wang R, Hofmann JN, Liao LM, Zeidan AM, Mesa R, Ma X. Lifestyle factors and risk of myeloproliferative neoplasms in the NIH‐AARP diet and health study. International Journal Of Cancer 2020, 147: 948-957. PMID: 31904114, PMCID: PMC8919268, DOI: 10.1002/ijc.32853.Peer-Reviewed Original ResearchConceptsNIH-AARP DietPolycythemia veraMyeloproliferative neoplasmsEssential thrombocythemiaHazard ratioLifestyle factorsCaffeine intakeHealth StudyMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelRisk of PVProportional hazards regression modelsRisk of MPNLarge prospective studiesHazards regression modelsConfidence intervalsPhiladelphia chromosome-negative myeloproliferative neoplasmsMPN riskOverall cohortProspective cohortProspective studyInverse associationRisk factorsPV riskProtective effect
2019
Trends and factors affecting the US adult hematology workforce: a mixed methods study
Sharma D, Wallace N, Levinsohn EA, Marshall AL, Kayoumi K, Madero J, Homer M, Reynolds R, Hafler J, Podoltsev NA, Lee AI. Trends and factors affecting the US adult hematology workforce: a mixed methods study. Blood Advances 2019, 3: 3550-3561. PMID: 31738829, PMCID: PMC6880914, DOI: 10.1182/bloodadvances.2019000307.Peer-Reviewed Original ResearchConceptsHematology/oncology fellowsBenign hematologyOncology fellowsASH annual meetingClinical care modelsMixed-methods studyMajority of fellowsAdult hematologistsSeparate focus groupsCare modelClinical careMethods studyFellowship program directorsFocus group participantsHematologyMore fellowsFellowship trainingSingle training programOncologyGroup participantsLongitudinal studyAmerican SocietyNational studyOncology facultyFocus group discussionsTemporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population‐level analysis
Zeidan AM, Podoltsev NA, Wang X, Bewersdorf JP, Shallis RM, Huntington SF, Gore SD, Davidoff AJ, Ma X, Wang R. Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population‐level analysis. Cancer 2019, 125: 4241-4251. PMID: 31483484, PMCID: PMC7733320, DOI: 10.1002/cncr.32439.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaTime of diagnosisOlder patientsActive treatmentMyeloid leukemiaMultivariable logistic regression modelMedian overall survivalPercentage of patientsLow-intensity therapyMajority of patientsNovel therapeutic optionsQuality of careLogistic regression modelsIntensity therapyTherapy receiptOverall survivalWorse survivalClinical factorsInferior survivalEntire cohortTherapeutic optionsPatient populationRetrospective analysisHigher oddsProvider characteristicsUnderutilization of guideline‐recommended supportive care among older adults with multiple myeloma in the United States
Giri S, Zhu W, Wang R, Zeidan A, Podoltsev N, Gore SD, Neparidze N, Ma X, Gross CP, Davidoff AJ, Huntington SF. Underutilization of guideline‐recommended supportive care among older adults with multiple myeloma in the United States. Cancer 2019, 125: 4084-4095. PMID: 31381151, DOI: 10.1002/cncr.32428.Peer-Reviewed Original ResearchConceptsBone-modifying drugsSupportive careMultiple myelomaInfluenza vaccinationAntiviral prophylaxisOlder adultsLower oddsEnd Results-Medicare databaseNon-Hispanic black patientsMultivariable logistic regression modelBaseline renal impairmentSupportive care useTreatment-related toxicityFacility-level characteristicsNon-Hispanic blacksOutcomes of interestCommunity-based settingsLogistic regression modelsRenal impairmentActive treatmentBlack patientsCare useConcomitant useProphylactic antiviralsReduced oddsRBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis
Zeidan AM, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis. Leukemia & Lymphoma 2019, 60: 3181-3187. PMID: 31170846, DOI: 10.1080/10428194.2019.1622700.Peer-Reviewed Original ResearchConceptsRBC transfusion independenceLR-MDS patientsTransfusion independenceHMA initiationRBC transfusionClinical effectivenessReal-life clinical effectivenessRed blood cell transfusionLower-risk myelodysplastic syndromesLow-risk MDS patientsRisk MDS patientsBlood cell transfusionRisk myelodysplastic syndromesHMA therapyLR-MDSCell transfusionMost patientsDisease courseMDS patientsMedicare databaseMyelodysplastic syndromePopulation-level estimatesLower oddsTransfusionPatientsGuadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. The Lancet Haematology 2019, 6: e317-e327. PMID: 31060979, PMCID: PMC9012213, DOI: 10.1016/s2352-3026(19)30029-8.Peer-Reviewed Original ResearchConceptsHigh-risk myelodysplastic syndromeMyelodysplastic syndromeRefractory cohortAdverse eventsRefractory diseaseHypomethylating agentEastern Cooperative Oncology Group performance statusNorth American medical centersInternational Prognostic Scoring SystemCommon grade 3Phase 2 partWorse adverse eventsOpen-label studyProportion of patientsPrognostic scoring systemOverall responseChronic myelomonocytic leukemiaNew therapeutic optionsAmerican medical centersEligible patientsFebrile neutropaeniaIntravenous decitabinePrimary endpointRefractory patientsStudy drugImpact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.
Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. Journal Of The National Comprehensive Cancer Network 2019, 17: 211-219. PMID: 30865915, DOI: 10.6004/jnccn.2018.7095.Peer-Reviewed Original ResearchConceptsImpact of hydroxyureaThrombotic eventsEssential thrombocythemiaEffect of hydroxyureaOlder patientsOverall survivalLower riskMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelHigh-risk essential thrombocythemiaProportional hazards regression modelsRetrospective cohort studyRisk of deathSEER-Medicare databaseHazards regression modelsRisk of thrombosisHU usersFrontline therapyCohort studyCurrent guidelinesStudy populationPatientsReal-world settingThrombosisOlder adults
2018
The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera
Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. Blood Advances 2018, 2: 2681-2690. PMID: 30333100, PMCID: PMC6199652, DOI: 10.1182/bloodadvances.2018021436.Peer-Reviewed Original ResearchConceptsRisk of thrombosisPV patientsOverall survivalThrombotic eventsMultivariable Cox proportional hazards modelsEnd Results-Medicare databaseHigh-risk PV patientsCox proportional hazards modelOlder adultsImpact of phlebotomyRetrospective cohort studyPopulation-based studyProportional hazards modelEffect of phlebotomyOutcomes of interestPolycythemia vera patientsContemporary clinical practiceImproved OSCohort studyCytoreductive therapyOlder patientsTherapeutic phlebotomyTreatment modalitiesCurrent guidelinesLower risk